147 related articles for article (PubMed ID: 31571107)
21.
Watanabe S; Tsuchiya K; Nishimura R; Shirasaki T; Katsukura N; Hibiya S; Okamoto R; Nakamura T; Watanabe M
Mol Cancer Res; 2019 Jul; 17(7):1459-1467. PubMed ID: 30988165
[TBL] [Abstract][Full Text] [Related]
22. Unlocking HDR-mediated nucleotide editing by identifying high-efficiency target sites using machine learning.
O'Brien AR; Wilson LOW; Burgio G; Bauer DC
Sci Rep; 2019 Feb; 9(1):2788. PubMed ID: 30808944
[TBL] [Abstract][Full Text] [Related]
23. CRISPR/Cas9-mediated deletion of Interleukin-30 suppresses IGF1 and CXCL5 and boosts SOCS3 reducing prostate cancer growth and mortality.
Sorrentino C; D'Antonio L; Ciummo SL; Fieni C; Landuzzi L; Ruzzi F; Vespa S; Lanuti P; Lotti LV; Lollini PL; Di Carlo E
J Hematol Oncol; 2022 Oct; 15(1):145. PubMed ID: 36224639
[TBL] [Abstract][Full Text] [Related]
24. Targeting mutant TP53 as a potential therapeutic strategy for the treatment of osteosarcoma.
Tang F; Min L; Seebacher NA; Li X; Zhou Y; Hornicek FJ; Wei Y; Tu C; Duan Z
J Orthop Res; 2019 Mar; 37(3):789-798. PubMed ID: 30667081
[TBL] [Abstract][Full Text] [Related]
25. RNA-Guided
Ittiprasert W; Chatupheeraphat C; Mann VH; Li W; Miller A; Ogunbayo T; Tran K; Alrefaei YN; Mentink-Kane M; Brindley PJ
Int J Mol Sci; 2022 Jan; 23(2):. PubMed ID: 35054816
[TBL] [Abstract][Full Text] [Related]
26. p53 inhibits CRISPR-Cas9 engineering in human pluripotent stem cells.
Ihry RJ; Worringer KA; Salick MR; Frias E; Ho D; Theriault K; Kommineni S; Chen J; Sondey M; Ye C; Randhawa R; Kulkarni T; Yang Z; McAllister G; Russ C; Reece-Hoyes J; Forrester W; Hoffman GR; Dolmetsch R; Kaykas A
Nat Med; 2018 Jul; 24(7):939-946. PubMed ID: 29892062
[TBL] [Abstract][Full Text] [Related]
27. The Effect of Gene Editing by CRISPR-Cas9 of miR-21 and the Indirect Target MMP9 in Metastatic Prostate Cancer.
Camargo JA; Viana NI; Pimenta R; Guimarães VR; Dos Santos GA; Candido P; Ghazarian V; Romão P; Silva IA; Birbrair A; Srougi M; Nahas WC; Leite KR; Trarbach EB; Reis ST
Int J Mol Sci; 2023 Oct; 24(19):. PubMed ID: 37834295
[TBL] [Abstract][Full Text] [Related]
28. The Disruption of Mage-11 Gene via CRISPR/Cas9 Method Induced Apoptosis in the in vitro Model of Prostate Cancer.
Farhadi L; Soleimani F; Fakhari S; Jalili A
Gulf J Oncolog; 2023 Jan; 1(41):7-16. PubMed ID: 36804154
[TBL] [Abstract][Full Text] [Related]
29. CRISPR/Cas9-mediated knockout of Lcn2 effectively enhanced CDDP-induced apoptosis and reduced cell migration capacity of PC3 cells.
Rahimi S; Roushandeh AM; Ebrahimi A; Samadani AA; Kuwahara Y; Roudkenar MH
Life Sci; 2019 Aug; 231():116586. PubMed ID: 31220528
[TBL] [Abstract][Full Text] [Related]
30. Dual-sgRNA CRISPR/Cas9 knockout of PD-L1 in human U87 glioblastoma tumor cells inhibits proliferation, invasion, and tumor-associated macrophage polarization.
Fierro J; DiPasquale J; Perez J; Chin B; Chokpapone Y; Tran AM; Holden A; Factoriza C; Sivagnanakumar N; Aguilar R; Mazal S; Lopez M; Dou H
Sci Rep; 2022 Feb; 12(1):2417. PubMed ID: 35165339
[TBL] [Abstract][Full Text] [Related]
31. Introduction of the FecG
Xu X; Zhang X; Peng X; Liu C; Li W; Liu M
Theriogenology; 2023 Feb; 197():177-185. PubMed ID: 36525857
[TBL] [Abstract][Full Text] [Related]
32. Covalent linkage of the DNA repair template to the CRISPR-Cas9 nuclease enhances homology-directed repair.
Savic N; Ringnalda FC; Lindsay H; Berk C; Bargsten K; Li Y; Neri D; Robinson MD; Ciaudo C; Hall J; Jinek M; Schwank G
Elife; 2018 May; 7():. PubMed ID: 29809142
[TBL] [Abstract][Full Text] [Related]
33. CRISPR/Cas9-mediated precise genome modification by a long ssDNA template in zebrafish.
Bai H; Liu L; An K; Lu X; Harrison M; Zhao Y; Yan R; Lu Z; Li S; Lin S; Liang F; Qin W
BMC Genomics; 2020 Jan; 21(1):67. PubMed ID: 31964350
[TBL] [Abstract][Full Text] [Related]
34. Restoring the p53 'Guardian' Phenotype in p53-Deficient Tumor Cells with CRISPR/Cas9.
Chira S; Gulei D; Hajitou A; Berindan-Neagoe I
Trends Biotechnol; 2018 Jul; 36(7):653-660. PubMed ID: 29478674
[TBL] [Abstract][Full Text] [Related]
35. Precision genome editing in the CRISPR era.
Salsman J; Dellaire G
Biochem Cell Biol; 2017 Apr; 95(2):187-201. PubMed ID: 28177771
[TBL] [Abstract][Full Text] [Related]
36. Quantitative assessment of HR and NHEJ activities via CRISPR/Cas9-induced oligodeoxynucleotide-mediated DSB repair.
Du J; Yin N; Xie T; Zheng Y; Xia N; Shang J; Chen F; Zhang H; Yu J; Liu F
DNA Repair (Amst); 2018 Oct; 70():67-71. PubMed ID: 30212742
[TBL] [Abstract][Full Text] [Related]
37. Cas9 activates the p53 pathway and selects for p53-inactivating mutations.
Enache OM; Rendo V; Abdusamad M; Lam D; Davison D; Pal S; Currimjee N; Hess J; Pantel S; Nag A; Thorner AR; Doench JG; Vazquez F; Beroukhim R; Golub TR; Ben-David U
Nat Genet; 2020 Jul; 52(7):662-668. PubMed ID: 32424350
[TBL] [Abstract][Full Text] [Related]
38. Generation of site-specific mutant mice using the CRISPR/Cas9 system.
Bai M; Li Q; Shao YJ; Huang YH; Li DL; Ma YL
Yi Chuan; 2015 Oct; 37(10):1029-35. PubMed ID: 26496755
[TBL] [Abstract][Full Text] [Related]
39. Introduction of a point mutation in the KRAS gene of in vitro fertilized porcine zygotes via electroporation of the CRISPR/Cas9 system with single-stranded oligodeoxynucleotides.
Wittayarat M; Hirata M; Namula Z; Sato Y; Nguyen NT; Le QA; Lin Q; Takebayashi K; Tanihara F; Otoi T
Anim Sci J; 2021; 92(1):e13534. PubMed ID: 33638256
[TBL] [Abstract][Full Text] [Related]
40. Application of prime editing system to introduce TP53 R248Q hotspot mutation in acute lymphoblastic leukemia cell line.
Nguyen T; Aida T; Iijima-Yamashita Y; Tamai M; Nagamachi A; Kagami K; Komatsu C; Kasai S; Akahane K; Goi K; Inaba T; Sanada M; Inukai T
Cancer Sci; 2024 Jun; 115(6):1924-1935. PubMed ID: 38549229
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
